WOOJUNG BIO, Inc. (KOSDAQ:215380)
South Korea
· Delayed Price · Currency is KRW 2,735.00
+630.00 (29.93%)
At close: Mar 6, 2026
WOOJUNG BIO Revenue
WOOJUNG BIO had revenue of 9.76B KRW in the quarter ending September 30, 2025, with 5.71% growth. This brings the company's revenue in the last twelve months to 37.12B, down -24.45% year-over-year. In the year 2024, WOOJUNG BIO had annual revenue of 43.20B with 11.87% growth.
Revenue (ttm)
37.12B
Revenue Growth
-24.45%
P/S Ratio
1.24
Revenue / Employee
n/a
Employees
n/a
Market Cap
46.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43.20B | 4.58B | 11.87% |
| Dec 31, 2023 | 38.62B | -8.30B | -17.70% |
| Dec 31, 2022 | 46.92B | 15.68B | 50.20% |
| Dec 31, 2021 | 31.24B | -6.11B | -16.35% |
| Dec 31, 2020 | 37.34B | 5.05B | 15.65% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| C&R Research | 63.97B |
| DT&CRO CO. | 44.36B |
| P&K Skin Research Center | 22.13B |
| SLS BIO | 5.47B |
| HLB bioStep | 71.47B |
| BioInfra | 21.92B |
| DreamCIS | 62.06B |
| Curachem | 6.02B |